Spago Nanomedical
0,26 SEK -21,21%Vær den første som følger denne virksomhed
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPAGO
Daglig lav / høj pris
0,258 / 0,324
SEK
Markedsværdi
90,53 mio. SEK
Aktieomsætning
55,91 t SEK
Volumen
184 t
Finanskalender
Delårsrapport
06.11.2024
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Peter Lindell | 45,5 % | 45,5 % |
| Mikael Lönn | 9,2 % | 9,2 % |
| Eva Redhe | 5,3 % | 5,3 % |
| Avanza Pension | 5,1 % | 5,1 % |
| Tiel Ridderstad | 3,9 % | 3,9 % |
| Nordnet Pensionsförsäkring | 2,8 % | 2,8 % |
| Filippa Lindström | 1,4 % | 1,4 % |
| Pension Futur | 1,0 % | 1,0 % |
| Philip Löchen | 0,9 % | 0,9 % |
| Thord Wilkne | 0,9 % | 0,9 % |
ViserAlle indholdstyper
Spago Nanomedical's Phase I/IIa study Tumorad-01 continues following successful treatment completion of first patient group
Redeye: Spago Nanomedical - Tumorad progress
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools